From reading the web articles I mainly see it is a revalidation of the pre-clinical work that was done in the 1980s - particularly for AML and Breast Cancer. Although the recent study does emphasise the strength / potency of Bisantrene as an anti-cancer agent in both AML and solid tumors.
So in general we have the Israel trial validating the historic in-human trials in a modern context and this study validating the historic preclinical work in a modern context.
I guess at some point RAC will announce results from their pre-clinical breast cancer work. We haven't seen anything announced yet about their preclinical AML work.
From reading the web articles I mainly see it is a revalidation...
-
- There are more pages in this discussion • 322 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 2376 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |